Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 89798, held by Cosette Pharms Nc. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 89798 (Triamcinolone Acetonide), held by Cosette Pharms Nc, was first approved by FDA on May 31, 1991, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 31, 1991 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% · cream;topical | Triamcinolone Acetonide | Rx |
| Oct 27, 2022 | Supplement 16Manufacturing | Approved | None posted |
| Apr 6, 2015 | Supplement 2Manufacturing | Approved | None posted |
| May 31, 1991 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
